Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
This is a prospective, open label study to evaluate the efficacy and safety of neoadjuvant pyrotinib in early breast cancer patients.
Breast Cancer Female
DRUG: Pyrotinib
pCR, pathological complete response, 1-2 weeks after surgery
This is a prospective, open label study to evaluate the efficacy and safety of neoadjuvant pyrotinib in early breast cancer patients.